AbstractTargeting leukemia initiating cells is considered to be an effective way to cure leukemia, for which it is critical to identify novel therapeutic targets. Herein, we demonstrate that CD244, which was initially reported as a key regulator for natural killer cells, is highly expressed on both mouse and human leukemia initiating cells. Upon CD244 knockdown, human leukemia cell lines and primary leukemia cells have markedly impaired proliferation abilities both in vitro and in vivo. Interestingly, the repopulation ability of both mouse and human hematopoietic stem cells is not impaired upon CD244 knockdown. Using an MLL-AF9-induced murine acute myeloid leukemia model, we show that leukemogenesis is dramatically delayed upon CD244 deletion, together with remarkably reduced Mac1+/c-Kit+ leukemia cells (enriched for leukemia initiating cells). Mechanistically, we reveal that CD244 is associated with c-Kit and p27 except for SHP-2 as previously reported. CD244 co-operates with c-Kit to activate SHP-2 signaling to dephosphorylate p27 and maintain its stability to promote leukemia development. Collectively, we provide intriguing evidence that the surface immune molecule CD244 plays an important role in the maintenance of stemness of leukemia initiating cells, but not in hematopoietic stem cells. CD244 may represent a novel therapeutic target for the treatment of acute myeloid leukemia.
It was suggested that leukemia initiating cells (LICs) or leukemia stem cells (LSCs) are responsible for initiation, development and relapse of leukemia. Identification of novel theraputic targets specific to LICs is the key for the eradication of leukemia. We previously identified that an immune inhibitory receptor, LILRB2, played an essential role in the stemness maintenance of LICs and hematopoietic stem cells (HSCs).1 Studies from other groups also suggest that targeting certain surface immune molecules of LICs may be an attractive way to block leukemogenesis.32 However, an ideal therapeutic target for leukemia treatment should only be essential for maintaining the pool of LICs, but not for HSCs. We hypothesized that other surface immune molecules, including both inhibitory and stimulatory receptors, may function differentially between HSCs and LICs.4 It is urgent to understand such molecules for the eradication of LICs.
CD244 is one of the immune molecules initially identified on natural killer (NK) cells, a subset of CD8 T cells and monocytes. It has been reported that CD244 is also highly expressed on human HSCs, but may not (or may rarely) be expressed on mouse HSCs,75 although its function is still not clear. CD244 is a member of the CD2 subset of the immunoglobulin superfamily with four immune-receptor based tyrosine switch motifs (ITSM)8 which can function as an activating or inhibitory receptor by alternative adaptor recruitments including SAP, EAT-2, SHP-2 and SHP-1. Human CD244 interacts with SAP to activate NK cells.109 However, in the absence of SAP, CD244 associates with the inhibitory phosphatase SHP-2 or SHP-1 to function as an inhibitory receptor.1211 CD244 is also known to associate with PI3K and SHIP1 as this receptor also signals through the inositol phospholipid signaling pathway.1513 Nevertheless, the functions of CD244 in leukemia development and the potential targets involved in CD244/SHP-2 signaling remain largely unknown.
In this study, we showed that knockdown of CD244 by shRNAs induced a marked decrease of the proliferation abilities in both human AML cell lines and primary LICs, but not in mouse and human HSCs. Furthermore, CD244 deletion remarkably delayed leukemogenesis and depleted LICs in a murine MLL-AF9-transduced AML model. CD244 co-operates with c-Kit and initiates downstream SHP-2/p27 signaling to manipulate the activities of LICs. Therefore, CD244 may be an ideal target for the eradication of acute myeloid LICs.
Lentivirus construction, infection and in vivo xenograft
The lentiviral vector PLL3.7 was used to express shRNAs designed to target CD244 (sequences are listed in Online Supplementary Table S1). Using a calcium phosphate transfection method, lentivirus constructs together with the packaging plasmids of pSPAX2 and pMD2G were mixed and transfected into 293T cells. Lentiviruses were used for the following infection on human leukemia cell lines, human cord blood CD34 HSCs or acute myeloid leukemia (AML) samples. Human cord blood CD34 HSCs were purified by using CD34 enrichment Kit (Miltenyi). Details of the clinical sample information are listed in Online Supplementary Table S2. Total AML cells from Samples #12 to #16, #19 and #20 (subtype, M5) were used for infection, in vitro colony assay and in vivo transplantation. MV4-11 cells (2.5×10), human cord blood CD34 HSCs (2×10) or primary AML cells (2×10) were resuspended in 200 μL or 50 μL (for primary AML cells) PBS and transplanted into sublethally irradiated (250 rad) NOD-SCID mice by either retro-orbital or intra-tibial injection. All the mice were sacrificed for determination of engraftment at 2–3 months post transplantation.
Retroviral infection, transplantation and flow cytometric analysis
MLL-AF9-expressing retroviruses were produced in 293T cells with an MSCV-MLL-AF9-IRES-YFP encoding plasmid.16 Lin fetal liver cells were isolated from wild-type (WT) and CD244 knockout (KO) mice and infected with MLL-AF9 retroviruses by two rounds of spinoculation in the presence of 4 μg/mL polybrene. Infected cells (200,000) were transplanted into lethally irradiated (1000 rad) C57BL/6 mice by retro-orbital injection. Indicated YFP bone marrow cells from primary transplanted mice were further infused into recipient mice for secondary transplantation or limiting dilution analysis. Flow cytometry and cell cycle analyses were performed as we described previously.1 For analysis of lineages and LICs, either peripheral blood or bone marrow cells were stained with anti-mouse Mac-1-APC, anti-mouse Gr-1-PE, anti-mouse CD3-APC, anti-mouse B220-PE, or anti-mouse c-Kit-PE antibodies (eBioscience). CD244 expression on human LICs or HSCs were labeled by the antibodies against human CD45 (FITC), Lineage marker (APC), CD34 (eFluor 450), CD38 (PE-Cy7), CD90 (PE-Cy5.5), CD45RA (PE), CD123 (PE) and CD244 (Biotin). Expression of CD244 and c-Kit on mouse or human LICs (or cell lines) were detected by anti-mouse CD244-PE or human CD244-APC and anti-human c-Kit-PE antibodies (eBioscience). Cell cycle status was measured with Ki-67/7-AAD (or Hoechst 33342) staining (BD Pharmingen) according to the manufacturer’s instructions.
Bone marrow mononuclear cells were obtained from the patients following diagnostic work at the Department of Hematology at Xinhua Hospital or the 1st People’s Hospital; human cord blood were obtained from the Department of Gynaecology and Obstetrics at the 6th People’s Hospital, Shanghai Jiao Tong University School of Medicine. Written informed consent was obtained from all of the patients and all the procedures were approved by the Ethics Committee for Medical Research (IRB) at Shanghai Jiao Tong University School of Medicine.
Methods related to mouse information, western blotting and co-immunoprecipitation, quantitative RT-PCR, colony forming unit assays, bone marrow transplantation and statistical analyses are available in the Online Supplementary Appendix.
CD244 is required for the proliferation of both human leukemia cell lines and acute myeloid LICs
To identify novel surface immune molecules (SIMs) that regulate the stemness of HSCs or LICs, we screened approximately 30 potential candidates that were known to be expressed on immune cells.17 As shown in Online Supplementary Figure S1A (mean fluorescence intensity) and Figure 1A (frequencies of SIM cells), we found that several immune receptors, including IREM-1, CD244 and JAM3, were highly expressed on both human CD34 hematopoietic stem/progenitor cells (HSPCs) and AML cells transduced with MLL-AF9 oncogene in human CD34 HSCs, MA9 cells.18 Intriguingly, one of these molecules, CD244, which is critical for functions of NK cells, was expressed at the highest level on both HSPCs and AML cells. To elucidate the roles of CD244 in human AML, we first examined the protein levels of CD244 on different human AML cell lines. Most of the AML cell lines expressed CD244, including Kasumi-1 (M2), NB4 (M3), HL-60 (M3), THP-1 (M5), U937 (M5), MV4-11 (M5) and HEL (M6) (Figure 1B). We then constructed several shRNAs to specifically knockdown CD244 to evaluate its roles in cell proliferation. shCD244#1 and shCD244#2 efficiently reduced the CD244 levels as compared with that in scrambled cells, respectively, measured by either flow cytometric analysis or quantitative RT-PCR (Figure 1C and D). Since shCD244#2 had the highest knockdown efficiency, it was mainly used for the following experiments to unravel the functions of CD244 in human leukemia cells.
We then down-regulated the expression of CD244 in MV4-11 cells with shCD244#2 and found that these cells had notable decreased proliferation ability in vitro even two days upon CD244 knockdown (Figure 1E). Meanwhile, shCD244#1 had a similar effect when it was used to knock down CD244 in MV4-11 cells (Online Supplementary Figure S1B). We also observed similar effects in other CD244-knockdown leukemia cell lines including HL-60, U937 and THP-1 (Online Supplementary Figure S1C–E). We then injected CD244-knockdown MV4-11 cells into NOD-SCID mice and demonstrated that loss of CD244 led to a significantly decreased engraftment compared to that in the control (6.29±4.35% vs. 63.90±1.21%) (Figure 1F).
To address the function of CD244 in human AML CD34 cells, we analyzed the levels of CD244 in different types of human AML samples (M2, M3, M4 and M5) (Online Supplementary Table S2) by flow cytometry and found that most of the AML CD34 cells (enriched for LICs) were positive for CD244. In contrast, most of the tested B-cell acute lymphoblastic leukemia (B-cell ALL) CD34 cells expressed at a much lower level of CD244 (Online Supplementary Figure S2A and B). Interestingly, CD244 also expressed on some CD34 cells including blasts. Because it has been reported that leukemia blasts have differentially expressed surface markers compared to the residual HPSCs, such as CD123 or CD45RA,2119 we further examined the CD244 level on the immunophenotypic CD45SSC LinCD34CD38CD90CD45RA or LinCD34CD38CD90CD123 CD34 blasts (CD34 LICs) and CD45SSC LinCD34CD38CD90CD45RA or CD45SSC LinCD34CD38CD90CD123 CD34 blasts (CD34 LICs). The flow cytometric analysis showed that almost all the CD34 blasts expressed CD244, while CD34 blasts had a significantly lower level of CD244 compared to that of CD34 ones (Online Supplementary Figure S2C). Interestingly, CD34 blasts, but not CD34 blasts, had similar CD244 expression level with LinCD34CD38CD90CD45RA or LinCD34CD38-CD90CD123 residual HSCs (Online Supplementary Figure S2D–F).
We then knocked down the CD244 levels in several human AML samples with shCD244#1 or shCD244#2. Consistently, the deletion of CD244 led to a notable delay in the growth of CD34 LICs by shCD244#2 or shCD244#1 (Online Supplementary Figure S3A). Moreover, the in vitro functional colony forming assay revealed a significant declination in colony numbers (Figure 1G and H). We further performed serial re-plating experiments with human AML cells upon the knockdown of CD244 (Online Supplementary Figure S3B and C), which showed that the colony numbers were significantly reduced after serial re-plating (Online Supplementary Figure S3D). Importantly, when human AML cells were knocked down by shCD244#2 targeting CD244 and transplanted into NOD-SCID mice, the engraftment was dramatically decreased compared to controls (Figure 1I and Online Supplementary Figure S3E). Since CD244 is also expressed on LinCD34CD38CD90CD45RA immunophenotypic human HSCs (Online Supplementary Figure S3F), but may not be expressed or may be expressed only in some fractions of mouse HSCs,75 we decided to investigate its role in human HSCs as well. Interestingly, no obvious proliferation defects were observed in CD244-knockdown human cord blood HSCs (Online Supplementary Figure S3G). Then CD244-knockdown HSCs were infused into NOD-SCID mice and the repopulation was analyzed at 12 weeks post transplantation, showing that CD244 was not required for the repopulation ability of HSCs (Figure 1J and Online Supplementary Figure S3H and I). We also examined the knockdown efficiency of CD244 in human HSCs after transplantation, where the stably engrafted GFP CB cells infected either by shCD244#2 or Scramble shRNA were gated for the analysis of CD244 expression, which showed that CD244 was decreased to around 67.5% of that in the control (Figure 1K). This may also indicate that the lack of phenotype might not be due to an escape mechanism by CD244-expressing HSCs.
CD244 promotes leukemogenesis in a murine AML model
We further used a transplantable murine AML model driven by the MLL-AF9 oncogene22 to extensively explore the function of CD244 in leukemia development. We first evaluated the protein levels of CD244 on WT leukemia cells (tagged with YFP) and found that more than 92.9% of them were positive for CD244 as compared to isotype control by flow cytometry (Figure 2A). We further monitored leukemia progression by determining WT and CD244-null (hereafter referred to as KO) circulating leukemia cells in peripheral blood (Online Supplementary Figure S4A), which only expressed myeloid cell markers (Mac-1 and Gr-1), but not lymphoid cell markers (CD3 and B220) (Online Supplementary Figure S4B and C). Surprisingly, we did not find significant differences either for the frequencies of YFP leukemia cells or the differentiation status as compared by the percentages of differentiated Mac-1/Gr-1 leukemia cells (Online Supplementary Figure S4). There was no significant change in survival between WT and CD244-null leukemic mice as well (Online Supplementary Figure S4D). Nevertheless, we observed a notable decrease of Mac-1/c-Kit LICs in the bone marrow of CD244-null primary recipients than WT ones (35.23±3.52% vs. 45.88±2.45%) (Figure 2B).
Thereby, we performed a secondary transplantation to further reveal the effect of CD244 in LICs. We found that CD244-null YFP leukemia cells in peripheral blood were dramatically reduced compared to WT counterparts at three weeks post transplantation (23.21±5.98% vs. 64.26±4.42%) (Figure 2C). Most importantly, recipients of MLL-AF9-transduced CD244-null cells had a markedly extended survival (57 vs. 33) (Figure 2D and Online Supplementary Figure S4E). We further performed the limiting dilution assay to evaluate the LIC frequency in CD244-null leukemia cells, which was markedly decreased compared to WT controls (1 in 724 vs. 1 in 59) (Online Supplementary Table S3). Consistently, we also found that the sizes of livers and spleens were much smaller in the mice transplanted with CD244-null AML cells (Figure 2E). This was further confirmed by histological hematoxylin & eosin staining, showing much less infiltration in the mice injected with CD244-null leukemia cells (Figure 2F). These results also indicate the loss of self-renewal ability in CD244-null LICs. Consistent with our observations in human HSCs, CD244-null mouse HSCs also had normal repopulation ability 20 weeks after transplantation (Figure 2G and H). Because we did not uncover drastic changes in primary recipients, we then mainly focused on the phenotypes in secondary recipients.
CD244 promotes the proliferation of LICs
To further characterize the CD244-null AML, we first examined the phenotypic LIC frequencies in the bone marrow and spleens of mice receiving leukemia cells from primary recipients, which was significantly reduced to 60.9% of that in WT counterparts in the bone marrow (27.54±1.60% vs. 45.21±1.47%) (Figure 3A). We also observed a similar trend in the leukemic spleens although it is not statistically different (Figure 3A). Consistently, we also found that there was a much lower frequency of CD244-null LinIL7-RSca-1c-KitCD34FcγR L-GMPs (enriched in LICs) compared to that of WT controls (Online Supplementary Figure 4F and G), which indicates CD244 may play a potential role in the maintenance of LICs. An in vitro colony-forming assay also illustrated that the clonogenic potential of CD244-null leukemia cells isolated from secondary recipients was greatly declined to 62.8%, 26.7% and 42.5% of that in WT counterparts upon first-third plating, respectively (Figure 3B), indicating a loss of self-renewal ability upon CD244 deletion. We then further performed a cell cycle analysis and found there was only slightly decreased G0 frequencies (representing a quiescent status) in CD244-null LICs than WT ones (9.65±0.63% vs. 12.75±0.79%) (Figure 3C). Although there is some evidence to show the loss of quiescence may lead to the exhaustion of LICs,23 the connection between quiescence and stemness in LICs is still controversial since several lines of studies also imply the existence of a subset of actively cycling, non-quiescent AML cells enriched for LIC activities.24 In addition, we also did not observe significant changes in apoptosis between WT and CD244-null LICs (Figure 3D). These results suggest that CD244 may play important roles in the proliferation (or self-renewal) rather than sustaining the quiescence or apoptosis of LICs.
CD244 manipulates p27 levels to maintain the proliferation ability of LICs
To understand the underlying mechanisms that affect the proliferation (or self-renewal) ability in CD244-null LICs, we performed quantitative RT-PCR with WT and CD244-null Mac-1/c-Kit LICs. Taking into account the phenotypes in mouse CD244-null and human CD244-knockdown LICs, we mainly focused on the changes of molecules related to cell cycle and self-renewal, which showed that p27 was significantly down-regulated in CD244-null LICs (Figure 4A). We further evaluated p27 levels by western blotting or immunofluorescence staining and demonstrated that p27 levels were strikingly reduced in CD244-null LICs (Figure 4B and C). In addition, we also isolated cyptoplasmic proteins from WT and CD244-null LICs and examined the p27 levels by western blot, which showed that there was a remarkable decrease of cytoplasmic p27, but not nuclear form of p27 (Figure 4D). Although the mRNA level of p16 was up-regulated almost 2-fold, the protein level of p16 was not significantly changed in CD244-null LICs (Online Supplementary Figure S5A), which indicates that p16 does not play an important role in the CD244-mediated leukemogenesis. Although it has been reported that p27 acts as a cell cycle inhibitor by interacting with CDK2 or CDK4, and may participate in sustaining the quiescent state in the MLL-leukemia cells,2625 p27 has also been reported to serve as cytoplasmic oncoprotein in BCR-ABL1 transformed chronic myeloid leukemia to promote cell growth and block apoptosis, rather than its effects on cyclin-dependent kinase (CDKs).27 We also noticed that the p27 was mainly located in cytoplasm and notably reduced in CD244-null Mac-1/c-Kit LICs (Figure 4C and D), indicating p27 may exert its additional effects (may enhance proliferation or self-renewal) on leukemia development. To confirm whether p27 is a direct downstream target for CD244, we overexpressed mouse p27 in both WT and CD244-null leukemia cells and transplanted them into the recipient mice. The mice transplanted with the p27-over-expressed CD244-null AML cells developed leukemia significantly faster than CD244-null control cells, which was comparable to WT counterparts (Figure 4E). Interestingly, the overexpression of p27 in WT leukemia cells slightly suppressed their proliferation (Figure 4E). These data also suggested that p27 may have a dose-dependent effect on leukemogenesis. The p27 levels in WT, CD244-null, p27-over-expressed WT and CD244-null AML cells after transplantation were further confirmed by western blotting (Figure 4F).
In addition, we have performed a functional assay by testing the colony forming ability in vitro to directly evaluate the p27 effect on the proliferation of LICs. Interestingly, the ectopic expression of p27 enhanced the proliferation of CD244-null LICs in vitro, but not WT ones (Figure 4G). However, high level of p27 had no impact on the cell cycle status of both WT and CD244-null leukemic blasts (Figure 4H). In contrast, we also noticed that the colonies derived from CD244-null leukemia cells appeared much smaller and more diffused compared to WT ones, which could be rescued by the p27 OE (Figure 4G), suggesting the cell division of CD244-null LICs was slowed down upon p27 deletion. In addition, we also revealed that apoptosis was not altered in CD244-null LICs (Figure 3D). Therefore, these results suggest that CD244 maintains leukemogenic potential of AML cells through p27, which may mainly contribute to the proliferation (or self-renewal ability), but less likely to the quiescence or apoptosis of LICs.
CD244 regulates the p27 stability through SHP-2 signaling
In consideration of the significant decrease of p27 expression levels in the CD244-null LICs, we decided to delineate how p27 is regulated by CD244. We first performed the co-immunoprecipitation assay to pull down CD244 in 293T cells and demonstrated that CD244 was associated with p27 (Figure 5A). We further examined whether the phosphatase, SHP-2, served as a mediator between CD244 and p27 since SHP-2 was known to be involved in CD244 signaling. Conceivably, SHP-2 was found to be interacted with CD244 (Figure 5A). Conversely, both CD244 and SHP-2 could also be co-immunoprecipitated by p27 (Figure 5B). p27 could also be detected when SHP-2 was pulled down from 293T cells (Figure 5C). Moreover, importantly, endogenous CD244 and p27 were associated with SHP-2 in primary mouse AML cells as determined by the co-immunoprecipitation experiment (Figure 5D).
Several studies show that tyrosine phosphorylation at Y88/Y89 of p27 leads to its conversion into a non-inhibitor of cyclin-CDK complex and is required for efficient phosphorylation on T187 by CDK2, followed by ubiquitination mediated degradation.22137 Recently, SHP-2 is reported to be a phosphatase for tyrosine dephosphorylation of p27 and can be translocated into nucleus upon stimulation and stabilizes the p27 protein levels in the cytoplasm of AML cells.2826 Indeed, overexpression of CD244 could dramatically up-regulate the phosphorylation of SHP-2 which substantially dephosphorylated p27 (Figure 5E). To reveal whether SHP-2 is a direct player for CD244 to dephosphorylate p27, we knocked down SHP-2 with a validated shSHP-2#3 (Online Supplementary Figure S5B) in CD244-over-expressed 293T cells and examined the phospho-p27 levels upon co-immunoprecipitation. Indeed, phoshpo-p27 was highly up-regulated after SHP-2 deletion (Figure 5F). Furthermore, we have performed the experiment in human primary AML cells to confirm the regulatory role of SHP-2. We demonstrated that the p-p27 was significantly elevated upon SHP-2 or CD244 knockdown in human primary AML cells (Figure 5G and Online Supplementary Figure S5C). Then we continued to knock down CD244 in HEL cells to examine the regulatory role of SHP-2. Interestingly, we did find that p-SHP-2 and p27 were notably reduced, which could be rescued by overexpressing SHP-2 in CD244-knockdown HEL cells (Figure 5H). Taken together, CD244 is associated with SHP-2 to down-regulate the phosphorylation of p27, which further sustains its stability.
CD244 interacts with c-Kit to maintain the stability of p27
c-Kit has been reported as a critical regulator for both HSCs and AML initiation through SHP-2 or SCL pathway. Constitutively, activation of c-Kit may lead to the marked acceleration of leukemia development.3429 Regarding the significant decrease of c-Kit LICs in CD244-null leukemic mice, we speculate that there is a connection between CD244, c-Kit and p27. Therefore, we conducted a co-immunoprecipitation experiment with overexpression of both Fc-tagged CD244 and c-Kit in 293T cells, followed by pull-down with either protein A beads or anti-c-Kit antibodies. CD244 was indeed associated with c-Kit (Figure 6A and B). We also provided further evidence to show that p27 was directly interacted with c-Kit when p27 was pulled down from 293T cells (Figure 6C). Consistently, we further confirmed the interactions of CD244, SHP-2 and c-Kit in leukemia cell line, HEL cells, which is an erythroid leukemia cell line expressing both CD244 and c-Kit (Figure 6D and E).
Recently, Marcelo et al. reported that c-Kit promoted the expression of p27 in hemogenic endothelial cells,35 which led us to further evaluate the relationship of c-Kit and p27 in leukemia cells. By using shKit#3 specifically targeting c-Kit (Online Supplementary Figure S5D), we knocked down c-Kit expression in HEL cells and demonstrated that knockdown of c-Kit could efficiently down-regulate phosphorylation of SHP-2 and total p27 expression levels, but enhance the p-p27 level (Figure 6F). Because HEL cells were JAK2 V617F positive and may exert artificial effect on SHP-2/p27 signaling, we have further performed the experiment related to the role of c-Kit on primary mouse AML cells. As shown in Figure 6G, we examined the c-Kit/SHP-2/p27 pathways in c-Kit or c-Kit mouse AML cells and demonstrated that c-Kit level indeed enhances the SHP-2 signaling to decrease the phosphorylation level of p27 to maintain the stability of total p27 expression.
Next, we pulled down p27 with the antibody specifically against p27 in WT and CD244-null AML cells, and revealed c-Kit, SHP-2 and CD244 were indeed directly associated with p27 in physiological conditions (Figure 6H and Online Supplementary Figure S5E). Phospho-SHP-2 level was also significantly decreased, which was concordant with increased level of phospho-p27 (Figure 6H and Online Supplementary Figure S5E). Importantly, the interactions between these three proteins were CD244-dependent since there were much lower levels of p-SHP-2 and c-Kit, or higher levels of p-p27 in CD244-null leukemia cells (Figure 6H and Online Supplementary Figure S5E). Although we found no significant difference in the phospho-SHP-2 level in the total lysate of WT and CD244-null AML cells, there was a remarkable decreased phospho-SHP-2 level in CD244-null AML cells when p27 was immunoprecipitated, indicating that only the p27-interacting form of SHP-2 was affected upon CD244 deletion (Figure 6H and Online Supplementary Figure S5E). These results suggest that CD244 might co-ordinate with c-Kit to regulate the levels of p27 through SHP-2 pathway to maintain the proliferation ability of LICs.
CD244 controls the proliferation of human leukemia cells through SHP-2/p27 signaling
To tease apart the CD244/SHP-2/p27 signaling in human leukemia cells, we examined the p27 levels in either CD244-silenced HEL cells or CD244-over-expressed K562 cells (expressing very low levels of CD244) by immunoblotting, which showed that p27 levels were also consistently down-regulated or up-regulated, respectively (Figure 7A and B). We then measured the expression levels of CD244 and c-Kit in CD34 cells (enriched for LICs) from several AML patients and demonstrated that 61.3% of CD34/CD244 leukemia cells were co-expressed with c-Kit, which was much higher than cord blood CD34/CD244 mononuclear cells (MNC) (61.31±14.42% vs. 8.61±2.25%) (Figure 7C). These results indicate that CD244 and c-Kit may also function synergistically in human LICs. We further isolated CD244-low and CD244-high leukemia cells and examined the phospho-SHP-2 and p27 level by immunofluorescence staining. The phospho-SHP-2 and p27 levels were much higher in the cytoplasm of CD244-high cells (Figure 7D).
We next examined the CD244/c-Kit/SHP-2/p27 signaling in human primary AML cells and revealed similar interactions among these molecules as in a mouse leukemia model, as analyzed by the co-immunoprecipitation experiments (Figure 7E). Furthermore, CD244 receptors of human CD34 LICs were cross-linked with the functional anti-CD244 antibodies to test whether the downstream SHP-2/p27 signaling could be efficiently induced. In line with the findings in mouse leukemia cells, phospho-SHP-2 and p27 levels were indeed increased, while p-p27 was consistently decreased upon the antibody stimulation in all the 3 tested human samples (Figure 7F). In summary, a working model is shown in Figure 7G, and our findings show that CD244 collaborates with c-Kit to regulate SHP-2 phosphatase activity to dephosphorylate and stabilize p27 in cytoplasm for maintaining the proliferation (self-renewal) ability of LICs.
In this study, we characterized CD244 function in AML initiating cells and provided solid evidence that CD244 has a differential effect on LICs compared to normal HSCs. We further revealed CD244 might co-operate with c-Kit to mediate its downstream signaling through SHP-2/p27 to regulate the proliferation (self-renewal) of LICs. To our knowledge, this is the first body of evidence showing that CD244 is critical for leukemia development. These results consolidated our previous hypothesis that immune inhibitory receptors are involved in maintenance of the stemness of HSCs and LICs. Intriguingly, our study also indicated that both ITIM and ITSM containing immune molecules may be essential for different types of leukemia.
Our previous findings suggested that many ITIM-containing immune molecules recruit SHP-2, SHP-1 or SHIP1 to initiate numerous downstream signaling pathways. Our current study also indicates that CD244 is also associated with SHP-2 as well as p27 to control leukemia development. Nonetheless, how CD244 exerts its effect on SHP-2 and p27 needs further clarification. Our data showed that CD244 could up-regulate p27 levels either through transactivation or post-translational modification. However, it is still not clear which pathway plays the dominant roles in leukemogenesis and how these dual functions are integrated. Meanwhile, how CD244 transactivates p27 is still a mystery. p27 is known to be important to maintain the repopulation ability and quiescence of HSCs by co-operating with p57.3736 p27 has also been found to play differential roles in different types of cells, including acting as a cell cycle inhibitor to maintain the quiescent status of LICs25 and enhancing the migration of mouse embryonic fibroblasts.38 Nevertheless, several studies claimed that LICs existed in a non-quiescent population of cells controlled by certain cyclins, such as cyclin D2.39 Iwasaki et al. also demonstrated that CD93 marks a non-quiescent human LIC population and regulates LIC self-renewal predominantly by silencing CDKN2B.24 Herein, we also found CD244 may sustain the proliferation ability of LICs by stabilizing p27 levels independent of cell cycle inhibition, suggesting cell cycle regulators play differential roles in normal or cancer stem cells, which is critical for the development of new strategies for cancer treatment.
Furthermore, our findings indicate that c-Kit may interact with CD244 to regulate the expression levels of p27. However, there are several intriguing questions that remain to be addressed. 1) Which domain of c-Kit interplays with CD244: the extra-cellular or intra-cellular domain? 2) How does c-Kit stabilize p27 levels through CD244? 3) Does CD244 up-regulate the expression of c-Kit? 4) Although it is well known that c-Kit has an important function in mouse LIC maintenance, its role in human LICs and related mechanisms remains elusive. We are currently in the process of investigating these issues to pinpoint the CD244/c-Kit/SHP-2/p27 signaling in LICs.
Our study indicates that CD244 is highly expressed on different types of AML, but may not be expressed on B-cell ALL, which suggests that the expression of CD244 may serve as a threshold for myeloid differentiation. Whether there are any other specific regulators controlling CD244 expression in LICs needs to be clarified. Determining the novel mechanisms controlling the expression and activation of CD244 will open a new avenue for treatment of AML. In conclusion, our results provide strong evidence that CD244 co-operates with c-Kit to regulate leukemogenesis through SHP-2/p27 signaling.
We thank Dr. Colin Stewart of the Frederick National Laboratory for Cancer Research for providing the CD244−/− mice. We appreciate the kindness of Dr. Yueying Wang at Ruijing Hospital, Shanghai, providing us with the plasmid c-Kit.
- ↵* FZ and XL contributed equally to this work
- Check the online version for the most updated information on this article, online supplements, and information on authorship & disclosures: www.haematologica.org/content/102/4/707
- FundingThis work was supported by grants from National Basic Research Program of China (973Program, 2014CB965000; NO2015CB910403), National Natural Science Foundation of China (81370654, 81422001, 81570093), the 1000-Youth Elite Program, the Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning, the Innovation Program of Shanghai Municipal Education Commission (13G20), 1R01CA172268, CPRIT RP140402, and Taishan Scholar Immunology Program.
- Received June 27, 2016.
- Accepted January 13, 2017.
- Zheng J, Umikawa M, Cui C. Inhibitory receptors bind ANGPTLs and support blood stem cells and leukaemia development. Nature. 2012; 485(7400):656-660. PubMedhttps://doi.org/10.1038/nature11095Google Scholar
- Majeti R, Chao MP, Alizadeh AA. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell. 2009; 138(2):286-299. PubMedhttps://doi.org/10.1016/j.cell.2009.05.045Google Scholar
- Chao MP, Alizadeh AA, Tang C. Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia. Cancer Res. 2011; 71(4):1374-1384. PubMedhttps://doi.org/10.1158/0008-5472.CAN-10-2238Google Scholar
- Zheng J, Song C, Zhang CC. A new chapter: hematopoietic stem cells are direct players in immunity. Cell Biosci. 2011; 1:33. PubMedGoogle Scholar
- Kiel MJ, Yilmaz OH, Iwashita T, Terhorst C, Morrison SJ. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell. 2005; 121(7):1109-1121. PubMedhttps://doi.org/10.1016/j.cell.2005.05.026Google Scholar
- Sintes J, Romero X, Marin P, Terhorst C, Engel P. Differential expression of CD150 (SLAM) family receptors by human hematopoietic stem and progenitor cells. Exp Hematol. 2008; 36(9):1199-1204. PubMedhttps://doi.org/10.1016/j.exphem.2008.03.015Google Scholar
- Oguro H, Ding L, Morrison SJ. SLAM family markers resolve functionally distinct subpopulations of hematopoietic stem cells and multipotent progenitors. Cell Stem Cell. 2013; 13(1):102-116. PubMedhttps://doi.org/10.1016/j.stem.2013.05.014Google Scholar
- Mathew PA, Garni-Wagner BA, Land K. Cloning and characterization of the 2B4 gene encoding a molecule associated with non-MHC-restricted killing mediated by activated natural killer cells and T cells. J Immunol. 1993; 151(10):5328-5337. PubMedGoogle Scholar
- Tangye SG, Lazetic S, Woollatt E, Sutherland GR, Lanier LL, Phillips JH. Cutting edge: human 2B4, an activating NK cell receptor, recruits the protein tyrosine phosphatase SHP-2 and the adaptor signaling protein SAP. J Immunol. 1999; 162(12):6981-6985. PubMedGoogle Scholar
- Sayos J, Nguyen KB, Wu C. Potential pathways for regulation of NK and T cell responses: differential X-linked lymphoproliferative syndrome gene product SAP interactions with SLAM and 2B4. Int Immunol. 2000; 12(12):1749-1757. PubMedhttps://doi.org/10.1093/intimm/12.12.1749Google Scholar
- Parolini S, Bottino C, Falco M. X-linked lymphoproliferative disease. 2B4 molecules displaying inhibitory rather than activating function are responsible for the inability of natural killer cells to kill Epstein-Barr virus-infected cells. J Exp Med. 2000; 192(3):337-346. PubMedhttps://doi.org/10.1084/jem.192.3.337Google Scholar
- Tangye SG, Phillips JH, Lanier LL, Nichols KE. Functional requirement for SAP in 2B4-mediated activation of human natural killer cells as revealed by the X-linked lymphoproliferative syndrome. J Immunol. 2000; 165(6):2932-2936. PubMedhttps://doi.org/10.4049/jimmunol.165.6.2932Google Scholar
- Eissmann P, Beauchamp L, Wooters J, Tilton JC, Long EO, Watzl C. Molecular basis for positive and negative signaling by the natural killer cell receptor 2B4 (CD244). Blood. 2005; 105(12):4722-4729. PubMedhttps://doi.org/10.1182/blood-2004-09-3796Google Scholar
- Wahle JA, Paraiso KH, Costello AL, Goll EL, Sentman CL, Kerr WG. Cutting edge: dominance by an MHC-independent inhibitory receptor compromises NK killing of complex targets. J Immunol. 2006; 176(12):7165-7169. PubMedhttps://doi.org/10.4049/jimmunol.176.12.7165Google Scholar
- Wahle JA, Paraiso KH, Kendig RD. Inappropriate recruitment and activity by the Src homology region 2 domain-containing phosphatase 1 (SHP1) is responsible for receptor dominance in the SHIP-deficient NK cell. J Immunol. 2007; 179(12):8009-8015. PubMedhttps://doi.org/10.4049/jimmunol.179.12.8009Google Scholar
- Krivtsov AV, Twomey D, Feng Z. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature. 2006; 442(7104):818-822. PubMedhttps://doi.org/10.1038/nature04980Google Scholar
- Zhu Y, Yao S, Chen L. Cell surface signaling molecules in the control of immune responses: a tide model. Immunity. 2011; 34(4):466-478. PubMedhttps://doi.org/10.1016/j.immuni.2011.04.008Google Scholar
- Wei J, Wunderlich M, Fox C. Microenvironment determines lineage fate in a human model of MLL-AF9 leukemia. Cancer Cell. 2008; 13(6):483-495. PubMedhttps://doi.org/10.1016/j.ccr.2008.04.020Google Scholar
- Goardon N, Marchi E, Atzberger A. Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. Cancer Cell. 2011; 19(1):138-152. PubMedhttps://doi.org/10.1016/j.ccr.2010.12.012Google Scholar
- Jin L, Lee EM, Ramshaw HS. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell. 2009; 5(1):31-42. PubMedhttps://doi.org/10.1016/j.stem.2009.04.018Google Scholar
- Jordan CT, Upchurch D, Szilvassy SJ. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia. 2000; 14(10):1777-1784. PubMedhttps://doi.org/10.1038/sj.leu.2401903Google Scholar
- Somervaille TC, Cleary ML. Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. Cancer Cell. 2006; 10(4):257-268. PubMedhttps://doi.org/10.1016/j.ccr.2006.08.020Google Scholar
- Lechman ER, Gentner B, Ng SW. miR-126 Regulates Distinct Self-Renewal Outcomes in Normal and Malignant Hematopoietic Stem Cells. Cancer Cell. 2016; 29(2):214-228. PubMedhttps://doi.org/10.1016/j.ccell.2015.12.011Google Scholar
- Iwasaki M, Liedtke M, Gentles AJ, Cleary ML. CD93 Marks a Non-Quiescent Human Leukemia Stem Cell Population and Is Required for Development of MLL-Rearranged Acute Myeloid Leukemia. Cell Stem Cell. 2015; 17(4):412-421. PubMedhttps://doi.org/10.1016/j.stem.2015.08.008Google Scholar
- Zhang J, Seet CS, Sun C. p27kip1 maintains a subset of leukemia stem cells in the quiescent state in murine MLL-leukemia. Mol Oncol. 2013; 7(6):1069-1082. Google Scholar
- Kardinal C, Dangers M, Kardinal A. Tyrosine phosphorylation modulates binding preference to cyclin-dependent kinases and subcellular localization of p27Kip1 in the acute promyelocytic leukemia cell line NB4. Blood. 2006; 107(3):1133-1140. PubMedhttps://doi.org/10.1182/blood-2005-05-1771Google Scholar
- Agarwal A, Mackenzie RJ, Besson A. BCR-ABL1 promotes leukemia by converting p27 into a cytoplasmic oncoprotein. Blood. 2014; 124(22):3260-3273. PubMedhttps://doi.org/10.1182/blood-2013-04-497040Google Scholar
- Tossidou I, Dangers M, Koch A, Brandt DT, Schiffer M, Kardinal C. Tyrosine phos phatase SHP-2 is a regulator of p27(Kip1) tyrosine phosphorylation. Cell Cycle. 2008; 7(24):3858-3868. PubMedhttps://doi.org/10.4161/cc.7.24.7260Google Scholar
- Scolnik MP, Morilla R, de Bracco MM, Catovsky D, Matutes E. CD34 and CD117 are overexpressed in AML and may be valuable to detect minimal residual disease. Leuk Res. 2002; 26(7):615-619. PubMedhttps://doi.org/10.1016/S0145-2126(01)00182-5Google Scholar
- Boissel N, Leroy H, Brethon B. Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia. 2006; 20(6):965-70. PubMedhttps://doi.org/10.1038/sj.leu.2404188Google Scholar
- Hassan HT. c-Kit expression in human normal and malignant stem cells prognostic and therapeutic implications. Leuk Res. 2009; 33(1):5-10. PubMedhttps://doi.org/10.1016/j.leukres.2008.06.011Google Scholar
- Chavez-Gonzalez A, Dorantes-Acosta E, Moreno-Lorenzana D, Alvarado-Moreno A, Arriaga-Pizano L, Mayani H. Expression of CD90, CD96, CD117, and CD123 on different hematopoietic cell populations from pediatric patients with acute myeloid leukemia. Arch Med Res. 2014; 45(4):343-350. Google Scholar
- Lacombe J, Krosl G, Tremblay M. Genetic interaction between Kit and Scl. Blood. 2013; 122(7):1150-1161. PubMedhttps://doi.org/10.1182/blood-2011-01-331819Google Scholar
- Zhu HH, Ji K, Alderson N. Kit-Shp2-Kit signaling acts to maintain a functional hematopoietic stem and progenitor cell pool. Blood. 2011; 117(20):5350-5361. PubMedhttps://doi.org/10.1182/blood-2011-01-333476Google Scholar
- Marcelo KL, Sills TM, Coskun S. Hemogenic endothelial cell specification requires c-Kit, Notch signaling, and p27-mediated cell-cycle control. Dev Cell. 2013; 27(5):504-515. PubMedhttps://doi.org/10.1016/j.devcel.2013.11.004Google Scholar
- Cheng T, Rodrigues N, Dombkowski D, Stier S, Scadden DT. Stem cell repopulation efficiency but not pool size is governed by p27(kip1). Nat Med. 2000; 6(11):1235-1240. PubMedhttps://doi.org/10.1038/81335Google Scholar
- Zou P, Yoshihara H, Hosokawa K. p57(Kip2) and p27(Kip1) cooperate to maintain hematopoietic stem cell quiescence through interactions with Hsc70. Cell Stem Cell. 2011; 9(3):247-261. PubMedhttps://doi.org/10.1016/j.stem.2011.07.003Google Scholar
- Zhang D, Wang Y, Liang Y. Loss of p27 upregulates MnSOD in a STAT3-dependent manner, disrupts intracellular redox activity and enhances cell migration. J Cell Sci. 2014; 127(Pt 13):2920-2933. PubMedhttps://doi.org/10.1242/jcs.148130Google Scholar
- Chen BB, Glasser JR, Coon TA. F-box protein FBXL2 targets cyclin D2 for ubiquitination and degradation to inhibit leukemic cell proliferation. Blood. 2012; 119(13):3132-3134. PubMedhttps://doi.org/10.1182/blood-2011-06-358911Google Scholar